Fluicell AB - Asset Resilience Ratio

Latest as of December 2025: 12.24%

Fluicell AB (FLUI) has an Asset Resilience Ratio of 12.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Skr2.26 Million

≈ $243.43K USD Cash + Short-term Investments

Total Assets

Skr18.48 Million

≈ $1.99 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Fluicell AB's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Fluicell AB to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Fluicell AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Fluicell AB worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr2.26 Million	12.24%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr2.26 Million	12.24%

Asset Resilience Insights

Moderate Liquidity: Fluicell AB has 12.24% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Fluicell AB Industry Peers by Asset Resilience Ratio

Compare Fluicell AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Fluicell AB (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Fluicell AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	12.24%	Skr2.26 Million ≈ $243.43K	Skr18.48 Million ≈ $1.99 Million	-50.18pp
2024-12-31	62.43%	Skr15.92 Million ≈ $1.71 Million	Skr25.51 Million ≈ $2.75 Million	+32.85pp
2023-12-31	29.58%	Skr2.76 Million ≈ $297.34K	Skr9.34 Million ≈ $1.01 Million	-47.41pp
2022-12-31	76.99%	Skr24.46 Million ≈ $2.63 Million	Skr31.77 Million ≈ $3.42 Million	+0.29pp
2021-12-31	76.70%	Skr20.69 Million ≈ $2.23 Million	Skr26.98 Million ≈ $2.90 Million	+0.98pp
2020-12-31	75.71%	Skr18.80 Million ≈ $2.02 Million	Skr24.83 Million ≈ $2.67 Million	+33.40pp
2019-12-31	42.32%	Skr8.44 Million ≈ $907.96K	Skr19.94 Million ≈ $2.15 Million	-43.27pp
2018-12-31	85.59%	Skr22.23 Million ≈ $2.39 Million	Skr25.97 Million ≈ $2.80 Million	+17.69pp
2017-12-31	67.91%	Skr7.83 Million ≈ $842.96K	Skr11.54 Million ≈ $1.24 Million	+28.30pp
2016-12-31	39.60%	Skr1.10 Million ≈ $118.27K	Skr2.77 Million ≈ $298.63K	--

pp = percentage points

About Fluicell AB

ST:FLUI Sweden Biotechnology

Market Cap

$4.51 Million

Skr41.90 Million SEK

Market Cap Rank

#28743 Global

#651 in Sweden

Share Price

Skr30.50

Change (1 day)

-1.93%

52-Week Range

Skr7.95 - Skr57.20

All Time High

Skr188.78